Press Release
Executive Chairman & CEO of AbilityPharma, Carles Domènech, is Elected as Member of the Board for the Spanish Bioindustry Association (ASEBIO) for the Second Time in a Row
December 14, 2021
About Ability Pharmaceuticals
Ability Pharmaceuticals (www.abilitypharma.com) is a biopharmaceutical company with a product, ABTL0812 in phase 2b clinical trials, focused on improving the future of oncology by developing innovative therapies that address unmet medical needs. In April 2016, AbilityPharma signed a territorial license agreement for ABTL0812 with SciClone Pharmaceuticals (Hong Kong) Development Co. Limited to develop and market the product in China.
Ability Pharmaceuticals is headquartered in Parc Tecnològic del Vallès and Parc de Recerca UAB (Cerdanyola del Vallès, Barcelona, Catalonia, Spain). Current shareholders include its founders, private investors, CDTI, the biotech venture capital firms Inveready, Fitalent and SODENA, the EIC Fund and SciClone Pharmaceuticals, and has the financial support from ACCIO (Government of Catalonia), CDTI, ICO, ENISA, the Ministry of Science & Innovation (Government of Spain) and the European Commission (H2020 Program, European Innovation Council).
Contact information:
Carles Domènech, PhD
Executive Chairman and CEO
Ability Pharmaceuticals
E-mail: media.relations@abilitypharma.com
Tel.: +34 935 824 411
LATEST NEWS
Press Release
IBRILATAZAR (ABTL0812) from AbilityPharma increases chemotherapy effectiveness by 40% in patients with endometrial cancer + infoPress Release
AbilityPharma receives WHO approval for its ABTL0812 anticancer drug to be named IBRILATAZAR + infoPress Release
AGC Pharma Chemicals and AbilityPharma work together to produce innovative treatment for pancreatic cancer + infoPress Release
AbilityPharma Announces € 7 Million Financing Round to Advance Development of its Clinical Phase 2b Autophagy Inducer ABTL0812 in Metastatic Pancreatic Cancer + infoPress Release
Ability Pharmaceuticals announces the presentation of the phase 2a results of ABTL0812 as first-line therapy in patients with lung cancer at the ASCO 2023 Annual Meeting in Chicago + infoPress Release
AbilityPharma Achieves the 30% of the Estimated Recruitment for their Phase 2b Clinical Trial with ABTL0812 + FOLFIRINOX as a First-Line Therapy Treatment in Advanced Pancreatic Cancer + infoPress Release
AbilityPharma Obtains 1,5M € of Non-Dilutive Funding from Next Generation EU Funds to Further Study the Anticancer Immunomodulatory Effects of ABTL0812 + infoPress Release
AbilityPharma will attend LSX investical showcase in London to meet with key investors and venture capital firms + info
